Clinical Trial Update: Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Cabaletta for safety, tolerability, and efficacy in oculopharyngeal muscular dystrophy has completed, with results posted in August 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oculopharyngeal Muscular Dystrophy

Drugs mentioned

• Cabaletta

Snippet

Sponsor: Bioblast Pharma Ltd. | Conditions: Oculopharyngeal Muscular Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2017-08-23